Cited 26 times in
Further increase of vancomycin-resistant Enterococcus faecium, amikacin- and fluoroquinolone-resistant Klebsiella pneumoniae, and imipenem-resistant Acinetobacter spp. in Korea: 2003 KONSAR surveillance
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 용동은 | - |
dc.contributor.author | 이경원 | - |
dc.date.accessioned | 2015-06-10T12:29:37Z | - |
dc.date.available | 2015-06-10T12:29:37Z | - |
dc.date.issued | 2006 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/109903 | - |
dc.description.abstract | Monitoring temporal trends of antimicrobial resistance can provide useful information for the empirical selection of antimicrobial agents to treat infected patients and for the control of nosocomial infections. In this study, we analyzed antimicrobial resistance of clinically relevant bacteria in 2003 at Korean hospitals and at a commercial laboratory. The following organism-antimicrobial agent resistance combinations were very prevalent: oxacillin-resistant Staphylococcus aureus (68%), expanded-spectrum cephalosporin-resistant Klebsiella pneumoniae (25%), and fluoroquinolone-resistant Escherichia coli (33%), Acinetobacter spp. (58%), and Pseudomonas aeruginosa (40%). Moreover, gradual increases in vancomycin-resistant Enterococcus faecium (20%), cefoxitin-resistant E. coli (10%) and K. pneumoniae (23%), and imipenem-resistant P. aeruginosa (20%) and Acinetobacter spp. (13%) were also observed. The resistance rates of Acinetobacter spp. to most antimicrobial agents at hospitals and at the commercial laboratory were similar. Among the Acinetobacter spp. isolated at a tertiary-care hospital, 46.2% were multidrug-resistant to 9-12 of 13 antimicrobial agents, and 18.3% were panresistant. The exclusion of duplicate isolates at a tertiary-care hospital significantly lowered the proportion of oxacillin-resistant S. aureus, vancomycin-resistant E. faecium, and fluoroquinolone-resistant E. coli. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 43~54 | - |
dc.relation.isPartOf | YONSEI MEDICAL JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Acinetobacter/drug effects | - |
dc.subject.MESH | Acinetobacter/isolation & purification | - |
dc.subject.MESH | Acinetobacter Infections/drug therapy | - |
dc.subject.MESH | Acinetobacter Infections/epidemiology | - |
dc.subject.MESH | Acinetobacter Infections/microbiology Amikacin/pharmacology | - |
dc.subject.MESH | Anti-Bacterial Agents/pharmacology* | - |
dc.subject.MESH | Drug Resistance, Bacterial* | - |
dc.subject.MESH | Enterococcus faecium/drug effects* | - |
dc.subject.MESH | Enterococcus faecium/isolation & purification | - |
dc.subject.MESH | Fluoroquinolones/pharmacology | - |
dc.subject.MESH | Gammaproteobacteria/drug effects* | - |
dc.subject.MESH | Gammaproteobacteria/isolation & purification | - |
dc.subject.MESH | Gram-Negative Bacterial Infections/drug therapy | - |
dc.subject.MESH | Gram-Negative Bacterial Infections/epidemiology | - |
dc.subject.MESH | Gram-Negative Bacterial Infections/microbiology* | - |
dc.subject.MESH | Gram-Positive Bacterial Infections/drug therapy | - |
dc.subject.MESH | Gram-Positive Bacterial Infections/epidemiology | - |
dc.subject.MESH | Gram-Positive Bacterial Infections/microbiology* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Imipenem/pharmacology | - |
dc.subject.MESH | Klebsiella Infections/drug therapy | - |
dc.subject.MESH | Klebsiella Infections/epidemiology | - |
dc.subject.MESH | Klebsiella Infections/microbiology | - |
dc.subject.MESH | Klebsiella pneumoniae/drug effects | - |
dc.subject.MESH | Klebsiella pneumoniae/isolation & purification | - |
dc.subject.MESH | Korea/epidemiology | - |
dc.subject.MESH | Microbial Sensitivity Tests | - |
dc.subject.MESH | Population Surveillance | - |
dc.subject.MESH | Vancomycin/pharmacology | - |
dc.subject.MESH | Vancomycin Resistance | - |
dc.title | Further increase of vancomycin-resistant Enterococcus faecium, amikacin- and fluoroquinolone-resistant Klebsiella pneumoniae, and imipenem-resistant Acinetobacter spp. in Korea: 2003 KONSAR surveillance | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Laboratory Medicine (진단검사의학) | - |
dc.contributor.googleauthor | Kyungwon Lee | - |
dc.contributor.googleauthor | Ki Hyung Park | - |
dc.contributor.googleauthor | Seok Hoon Jeong | - |
dc.contributor.googleauthor | Hwan Sub Lim | - |
dc.contributor.googleauthor | Jong Hee Shin | - |
dc.contributor.googleauthor | Dongeun Yong | - |
dc.contributor.googleauthor | Gyoung-yim Ha | - |
dc.contributor.googleauthor | Yunsop Chong | - |
dc.identifier.doi | 10.3349/ymj.2006.47.1.43 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A02423 | - |
dc.contributor.localId | A02649 | - |
dc.relation.journalcode | J02813 | - |
dc.identifier.eissn | 1976-2437 | - |
dc.identifier.pmid | 16502484 | - |
dc.subject.keyword | Antimicrobial resistance surveillance | - |
dc.subject.keyword | Korea | - |
dc.subject.keyword | vancomycin resistance | - |
dc.subject.keyword | fluoroquinolone resistance | - |
dc.subject.keyword | imipenem resistance | - |
dc.contributor.alternativeName | Yong, Dong Eun | - |
dc.contributor.alternativeName | Lee, Kyung Won | - |
dc.contributor.affiliatedAuthor | Yong, Dong Eun | - |
dc.contributor.affiliatedAuthor | Lee, Kyung Won | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 47 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 43 | - |
dc.citation.endPage | 54 | - |
dc.identifier.bibliographicCitation | YONSEI MEDICAL JOURNAL, Vol.47(1) : 43-54, 2006 | - |
dc.identifier.rimsid | 55004 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.